Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Niobium tungstate compound for resisting hepatitis virus

A niobium tungstate compound, anti-hepatitis virus technology, applied in the field of niobium tungstate compounds for anti-hepatitis virus

Inactive Publication Date: 2010-09-29
JILIN UNIV
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the in vivo and in vitro toxicity of the rare earth heteropoly compounds in the above reports and patents is significantly higher than that of the niobium tungstate compounds in the present invention

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Niobium tungstate compound for resisting hepatitis virus
  • Niobium tungstate compound for resisting hepatitis virus
  • Niobium tungstate compound for resisting hepatitis virus

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Anti-hepatitis virus niobium tungstate compound Na 7 [Ge(NbO 2 ) 3 W 9 o 37 ]·15H 2 Preparation of O.

[0060] a. Dissolve 3.9g of sodium hydroxide in a nickel crucible, dissolve at 350°C, and slowly add 3.3g of Nb 2 o 5 , heated for 30 minutes, then cooled to room temperature, added to 50mL of deionized water, and left at 0°C for 12 hours to generate needle-like crystal products, and the hexaniobate compound Na7H[Nb 6 o 19 ];

[0061] b. Dissolve 11g of sodium germanate in 250mL of distilled water, and add 100g of sodium tungstate dihydrate while stirring. Slowly add 6mol / L concentrated hydrochloric acid solution to adjust the pH value of the solution to 8-9, a small amount of white precipitate is produced, the precipitate is suction filtered, and the filtrate is placed at 4°C for 2-3 days to obtain a white needle-shaped crystal vacancy heteropoly compound Na 9 H[GeW 9 o 34 ], wash the crystals with cold water, ethanol, ether for later use;

[0062] c. the 8...

Embodiment 2

[0064] Anti-hepatitis virus niobium tungstate compound K 7 [Si(NbO 2 ) 3 W 9 o 37 ]·14.5H 2 Preparation of O.

[0065] a. Dissolve 5.5g of potassium hydroxide in a nickel crucible, dissolve at 320°C, and slowly add 3.3g of Nb 2 o 5 , heated for 30 minutes, then cooled to room temperature, added to 50 mL of deionized water, and left at 0°C for 12 hours to form a needle-like crystal product and obtain hexaniobate compound K 7 H[Nb 6 o 19 ];

[0066] b. Dissolve 12g of sodium silicate in 250mL of distilled water, add 150g of sodium tungstate dihydrate while stirring, slowly add 6mol / L concentrated hydrochloric acid solution to adjust the pH value of the solution to 8.2, a small amount of white precipitate is produced, and the precipitate is suction filtered, and the filtrate Placed at 4°C for 2-3 days, a white needle-like crystal vacancy type heteropoly compound Na appears 9 H[SiW 9 o 34 ], wash the crystals with cold water, ethanol, ether for later use;

[0067] c....

Embodiment 3

[0069] Anti-hepatitis virus niobium tungstate compound Cs 6 H[Si(NbO 2 ) 3 W 9 o 37 ]·2H 2 Preparation of O.

[0070] a. same as embodiment 2 step a, make hexaniobate compound K 7 H[Nb 6 o 19 ];

[0071] b. same as Example 2, step b, to prepare the vacancy type heteropoly compound Na 9 H[SiW 9 o 34 ];

[0072] c. the 6.5g K obtained in step a 7 H[Nb 6 o 19 ] was dissolved in 400mL deionized water, then 40mL hydrogen peroxide was added in this niobate aqueous solution, acidified with about 20mL of 3mol / L hydrochloric acid, and then 25.1g of Na 9 H[SiW 9 o 34 ] into the niobate solution, dilute to 700mL with water, stir gradually to form a clear, dark yellow solution, add 10g of CsCl precipitant, evaporate the solution to 350mL at room temperature, filter, and wash with distilled water at 4°C to obtain a yellow solid Cs 6 H[Si(NbO 2 ) 3 W 9 o 37 ]·2H 2 O.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a niobium tungstate compound for resisting hepatitis virus, which has the function of resisting the hepatitis virus and the chemical formula of AmBr (X (NbO2) 3W9O37). nH2O, wherein A is alkali metal ion Li, Na, K or Cs; B is hydrogen cation H+, ammonium ion NH4+ or amino acid cation; X is Si, Ge or P; and m=0-7, r=0-7 and n=0-20. The niobium tungstate compound is taken as active ingredient which is assisted by carrier or auxiliary material that is pharmaceutically acceptable, thus being used for preparing oral preparation or injection medicine applied to treating hepatitis. Compared with the existing medicine which is applied to treating hepatitis clinically, the niobium tungstate compound has the advantages of better liver target, low effective therapeutic dose, higher therapeutic index and lower toxicity, thus being an antiviral compound which has higher efficiency and is safer.

Description

technical field [0001] The invention belongs to the research on chemically synthesized drugs against hepatitis virus, in particular to a niobium tungstate compound with anti-hepatitis virus effect and its application. Background technique [0002] Viruses are one of the important pathogens that cause human infectious diseases. Among human infectious diseases, diseases caused by viruses account for about 3 / 4. Diseases caused by viruses have the characteristics of strong infectivity, wide prevalence and high incidence. For example, hepatitis B caused by hepatitis B virus has infected more than 2 billion people in the world, of which China accounts for about 1 / 3. Studies have shown that hepatitis B patients are 200-250 times more likely to develop liver cirrhosis and hepatocellular carcinoma than normal people, and 25%-40% of infected people are fatal; serious harm and cause huge economic losses. So far, there is no effective way for humans to treat diseases caused by hepat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C01G41/00A61K33/24A61K33/42C07F19/00A61K31/695A61P1/16A61P31/20
Inventor 李娟牛俊奇齐燕飞姜艳芳王娟张红李金华原野孟凡旭宋秀玲
Owner JILIN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products